Yingyi H. He

9 Jinsui Road
Guangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Retraction notice to "Volatile anesthetics sevoflurane targets leukemia stem/progenitor cells via Wnt/β-catenin inhibition" [Biomed. Pharmacother. 107 (2018), 1294-1301].

Retraction notice to "Volatile anesthetics sevoflurane targets leukemia stem/progenitor cells via Wnt/β-catenin inhibition" [Biomed. Pharmacother. 107 (2018), 1294-1301].

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: March 11, 2026

Disseminated mucormycosis leading to a fatal gastrointestinal perforation in a pediatric case of EBV-associated Hemophagocytic lymphohistiocytosis.

Disseminated mucormycosis leading to a fatal gastrointestinal perforation in a pediatric case of EBV-associated Hemophagocytic lymphohistiocytosis.

Journal: Medical mycology case reports

Published: September 08, 2025

PSGL-1 is a phagocytosis checkpoint that enables tumor escape from macrophage clearance.

PSGL-1 is a phagocytosis checkpoint that enables tumor escape from macrophage clearance.

Journal: Science immunology

Published: June 13, 2025

Long-term trends and disparities in primary intracranial germ cell tumor incidence and mortality for child and adolescent in the USA.

Long-term trends and disparities in primary intracranial germ cell tumor incidence and mortality for child and adolescent in the USA.

Journal: Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery

Published: June 01, 2025

Real-world Hepatobiliary Toxicity After Bispecific T-Cell Engager Therapy: A 10-Year Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System and the World Health Organization's Global Individual Case Safety Report Database.

Real-world Hepatobiliary Toxicity After Bispecific T-Cell Engager Therapy: A 10-Year Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System and the World Health Organization's Global Individual Case Safety Report Database.

Journal: Clinical therapeutics

Published: May 06, 2025

Allelic expression imbalance of CDKN2A variants in childhood acute lymphoblastic leukemia.

Allelic expression imbalance of CDKN2A variants in childhood acute lymphoblastic leukemia.

Journal: Cellular oncology (Dordrecht, Netherlands)

Published: February 20, 2025

A multicenter single-arm clinical study of Chinese children's cancer group-acute promyelocytic leukemia-2017 (CCCG-APL-2017) protocol.

A multicenter single-arm clinical study of Chinese children's cancer group-acute promyelocytic leukemia-2017 (CCCG-APL-2017) protocol.

Journal: Signal transduction and targeted therapy

Published: December 02, 2024

Prognostic implications of CD9 in childhood acute lymphoblastic leukemia: insights from a nationwide multicenter study in China.

Prognostic implications of CD9 in childhood acute lymphoblastic leukemia: insights from a nationwide multicenter study in China.

Journal: Leukemia

Published: September 16, 2023

Prognostic significance of multiparametric flow cytometry minimal residual disease at two time points after induction in pediatric acute myeloid leukemia.

Prognostic significance of multiparametric flow cytometry minimal residual disease at two time points after induction in pediatric acute myeloid leukemia.

Journal: BMC cancer

Published: May 09, 2023

Safety and Effectiveness of Rasburicase in the Control of Hyperuricemia in Pediatric Patients with Non-Hodgkin's Lymphoma and Acute Leukemia: An Open-Label, Single-Arm, Multi-center, Interventional Study.

Safety and Effectiveness of Rasburicase in the Control of Hyperuricemia in Pediatric Patients with Non-Hodgkin's Lymphoma and Acute Leukemia: An Open-Label, Single-Arm, Multi-center, Interventional Study.

Journal: Drugs in R&D

Published: March 29, 2023

Anti-CLL1-based CAR T-cells with 4-1-BB or CD28/CD27 stimulatory domains in treating childhood refractory/relapsed acute myeloid leukemia.

Anti-CLL1-based CAR T-cells with 4-1-BB or CD28/CD27 stimulatory domains in treating childhood refractory/relapsed acute myeloid leukemia.

Journal: Cancer medicine

Published: November 11, 2022

Clinical characteristics and prognosis analysis of patients with de novo ASXL1-mutated AML treated with the C-HUNAN-AML-15 protocol: A multicenter study by the South China Pediatric AML Collaborative Group.

Clinical characteristics and prognosis analysis of patients with de novo ASXL1-mutated AML treated with the C-HUNAN-AML-15 protocol: A multicenter study by the South China Pediatric AML Collaborative Group.

Journal: Cancer medicine

Published: September 22, 2022

Showing 1-12 of 31

Last Updated: 09/26/2026